[1]
|
Dalmau, J. and Graus, F. (2023) Diagnostic Criteria for Autoimmune Encephalitis: Utility and Pitfalls for Anti-body-Negative Disease. The Lancet Neurology, 22, 529-540. https://doi.org/10.1016/S1474-4422(23)00083-2
|
[2]
|
Ren, H., Fan, S., Zhao, Y. and Guan, H.Z. (2021) The Changing Spectrum of Antibody-Mediated Encephalitis in China. Journal of Neuroimmunology, 361, Article ID: 577753. https://doi.org/10.1016/j.jneuroim.2021.577753
|
[3]
|
Titulaer, M.J., McCracken, L., Gabilondo, I., et al. (2013) Treatment and Prognostic Factors for Long-Term Outcome in Patients with Anti-NMDA Receptor Encephalitis: An Ob-servational Cohort Study. The Lancet Neurology, 12, 157-165. https://doi.org/10.1016/S1474-4422(12)70310-1
|
[4]
|
Nosadini, M., Eyre, M., Molteni, E., et al. (2021) Use and Safety of Immunotherapeutic Management of N-Methyl- d-Aspartate Receptor Antibody Encephalitis: A Meta-Analysis. JAMA Neurology, 78, 1333-1344.
https://doi.org/10.1001/jamaneurol.2021.3188
|
[5]
|
Graus, F., Titulaer, M.J., Balu, R., et al. (2016) A Clinical Ap-proach to Diagnosis of Autoimmune Encephalitis. The Lancet Neurology, 15, 391-404. https://doi.org/10.1016/S1474-4422(15)00401-9
|
[6]
|
Dubey, D., Pittock, S.J., Kelly, C.R., et al. (2018) Autoim-mune Encephalitis Epidemiology and a Comparison to Infectious Encephalitis. Annals of Neurology, 83, 166-177. https://doi.org/10.1002/ana.25131
|
[7]
|
Gresa-Arribas, N., Planagumà, J., Petit-Pedrol, M., et al. (2016) Human Neurexin-3α Antibodies Associate with Encephalitis and Alter Synapse Development. Neurology, 86, 2235-2242. https://doi.org/10.1212/WNL.0000000000002775
|
[8]
|
中华医学会神经病学分会神经感染性疾病与脑脊液细胞学学组. 中国自身免疫性脑炎诊治专家共识(2022年版) [J]. 中华神经科杂志, 2022, 55(9): 931-949.
|
[9]
|
Ringelstein, M., Ayzenberg, I., Lindenblatt, G., et al. (2022) Interleukin-6 Receptor Blockade in Treat-ment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. Neurology Neuroim-munology & Neuroinflammation, 9, e1100. https://doi.org/10.1212/NXI.0000000000001100
|
[10]
|
Yamamura, T., Kleiter, I., Fujihara, K., et al. (2019) Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. New England Journal of Medicine, 381, 2114-2124. https://doi.org/10.1056/NEJMoa1901747
|
[11]
|
Lee, W., Lee, S., Moon, J., et al. (2016) Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study. Neurother-apeutics, 13, 824-832. https://doi.org/10.1007/s13311-016-0442-6
|
[12]
|
Lee, W., Lee, S., Shin, Y., et al. (2021) Teratoma Removal, Steroid, IVIG, Rituximab and Tocilizumab (T-SIRT) in Anti-NMDAR Encephalitis. Neurotherapeu-tics, 18, 474-487. https://doi.org/10.1007/s13311-020-00921-7
|
[13]
|
Randell, R.L., Adams, A.V. and Van Mater, H. (2018) Tocilizumab in Refractory Autoimmune Encephalitis: A Series of Pediatric Cases. Pediatric Neurology, 86, 66-68. https://doi.org/10.1016/j.pediatrneurol.2018.07.016
|
[14]
|
Benucci, M., Tramacere, L., Infantino, M., et al. (2020) Efficacy of Tocilizumab in Limbic Encephalitis with Anti-CASPR2 Antibodies. Case Reports in Neurological Medicine, 2020, Article ID: 5697670.
https://doi.org/10.1155/2020/5697670
|
[15]
|
Jaafar, F., Haddad, L., Koleilat, N., et al. (2020) Super Refractory Sta-tus Epilepticus Secondary to Anti-GAD Antibody Encephalitis Successfully Treated with Aggressive Immunotherapy. Epilepsy & Behavior Reports, 14, Article ID: 100396. https://doi.org/10.1016/j.ebr.2020.100396
|
[16]
|
Krogias, C., Hoepner, R., Müller, A., et al. (2013) Successful Treatment of Anti-Caspr2 Syndrome by Interleukin 6 Receptor Block-ade through Tocilizumab. JAMA Neurology, 70, 1056-1059.
https://doi.org/10.1001/jamaneurol.2013.143
|
[17]
|
Yu, A., Zhu, L., Altman, N.H. and Malek, T.R. (2009) A Low Interleukin-2 Receptor Signaling Threshold Supports the Development and Homeostasis of T Regulatory Cells. Immunity, 30, 204-217.
https://doi.org/10.1016/j.immuni.2008.11.014
|
[18]
|
Lim, J., Lee, S., Moon, J., et al. (2016) New Feasible Treatment for Refractory Autoimmune Encephalitis: Low-Dose Interleukin-2. Journal of Neuroimmunology, 299, 107-111. https://doi.org/10.1016/j.jneuroim.2016.09.001
|
[19]
|
Widman, G., Golombeck, K., Hautzel, H., et al. (2015) Treat-ing a GAD65 Antibody-Associated Limbic Encephalitis with Basiliximab: A Case Study. Frontiers in Neurology, 6, Ar-ticle 167. https://doi.org/10.3389/fneur.2015.00167
|
[20]
|
Choi, C.H., Ma, S.H., Ma, K.K., et al. (2021) Su-per-Refractory Status Epilepticus in Autoimmune Encephalitis Treated with Interleukin-1 Receptor Antagonist, Anakinra. Epileptic Disorders, 23, 500-505.
https://doi.org/10.1684/epd.2021.1283
|
[21]
|
Jang, Y., Woo, K.A., Lee, S.T., et al. (2018) Cerebral Autoinflamma-tory Disease Treated with Anakinra. Annals of Clinical and Translational Neurology, 5, 1428-1433. https://doi.org/10.1002/acn3.656
|
[22]
|
Jang, Y., Lee, W.J., Lee, H.S., et al. (2022) Anakinra Treatment for Refrac-tory Cerebral Autoinflammatory Responses. Annals of Clinical and Translational Neurology, 9, 91-97. https://doi.org/10.1002/acn3.51500
|
[23]
|
Taraschenko, O., Fox, H.S., Zekeridou, A., et al. (2021) Seizures and Memory Impairment Induced by Patient-Derived Anti-N-Methyl-D-Aspartate Receptor Antibodies in Mice Are Attenu-ated by Anakinra, an Interleukin-1 Receptor Antagonist. Epilepsia, 62, 671-682. https://doi.org/10.1111/epi.16838
|
[24]
|
Jang, Y., Lee, W.J., Lee, H.S., et al. (2021) Tofacitinib Treatment for Re-fractory Autoimmune Encephalitis. Epilepsia, 62, e53-e59. https://doi.org/10.1111/epi.16848
|
[25]
|
Massoud, F., Ismail, I.I., Al-Hashel, J.Y. and Abboud, H. (2020) CNS Demyelination during Tofacitinib Therapy: First Report. Multi-ple Sclerosis and Related Disorders, 46, Article ID: 102568. https://doi.org/10.1016/j.msard.2020.102568
|
[26]
|
Ito, S. (2020) Proteasome Inhibitors for the Treatment of Multiple Myeloma. Cancers, 12, Article 265.
https://doi.org/10.3390/cancers12020265
|
[27]
|
Sun, B., Ramberger, M., O’Connor, K.C., et al. (2020) The B Cell Immunobiology That Underlies CNS Autoantibody-Mediated Diseases. Nature Reviews Neurology, 16, 481-492. https://doi.org/10.1038/s41582-020-0381-z
|
[28]
|
Alexander, T., Sarfert, R., Klotsche, J., et al. (2015) The Pro-teasome Inhibitior Bortezomib Depletes Plasma Cells and Ameliorates Clinical Manifestations of Refractory Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 74, 1474-1478. https://doi.org/10.1136/annrheumdis-2014-206016
|
[29]
|
Scheibe, F., Ostendorf, L., Reincke, S.M., Prüss, H., et al. (2020) Daratumumab Treatment for Therapy-Refractory Anti-CASPR2 Encephalitis. Journal of Neurology, 267, 317-323. https://doi.org/10.1007/s00415-019-09585-6
|
[30]
|
Scheibe, F., Prüss, H., Mengel, A.M., et al. (2017) Bortezomib for Treatment of Therapy-Refractory Anti-NMDA Receptor Encephalitis. Neurology, 88, 366-370. https://doi.org/10.1212/WNL.0000000000003536
|
[31]
|
Behrendt, V., Krogias, C., Reinacher-Schick, A., et al. (2016) Bortezomib Treatment for Patients with Anti-N-Methyl- d-Aspartate Receptor Encephalitis. JAMA Neurology, 73, 1251-1253.
https://doi.org/10.1001/jamaneurol.2016.2588
|
[32]
|
Wang, T., Wang, B., Zeng, Z., et al. (2021) Efficacy and Safety of Bortezomib in Rituximab-Resistant Anti-N-Methyl- d-Aspartate Receptor (Anti-NMDAR) Encephalitis as Well as the Clinical Characteristics: An Observational Study. Journal of Neuroimmunology, 354, Article ID: 577527. https://doi.org/10.1016/j.jneuroim.2021.577527
|
[33]
|
Govil-Dalela, T., Datta, I. and Williams, M. (2021) Refractory NMDA-Receptor Encephalitis in a Teenager: A Novel Use of Bortezomib. Journal of Neuroimmunology, 355, Article ID: 577565.
https://doi.org/10.1016/j.jneuroim.2021.577565
|
[34]
|
Shin, Y.W., Lee, S.T., Kim, T.J., et al. (2018) Bortezomib Treatment for Severe Refractory Anti-NMDA Receptor Encephalitis. Annals of Clinical and Translational Neurology, 5, 598-605. https://doi.org/10.1002/acn3.557
|
[35]
|
Dinoto, A., Cheli, M., Bratina, A., Sartori, A. and Manganotti, P. (2021) Bortezomib in Anti-N-Methyl-d-Aspartate- Receptor (NMDA-R) Encephalitis: A Systematic Review. Journal of Neuroimmunology, 356, Article ID: 577586.
https://doi.org/10.1016/j.jneuroim.2021.577586
|
[36]
|
Lokhorst, H.M., Plesner, T., Laubach, J.P., et al. (2015) Tar-geting CD38 with Daratumumab Monotherapy in Multiple Myeloma. New England Journal of Medicine, 373, 1207-1219. https://doi.org/10.1056/NEJMoa1506348
|
[37]
|
Vercruyssen, M., El Hachem, G. and Maerevoet, M. (2018) The Daratumumab Crosses the Blood Brain Barrier. Clinical Lymphoma, Myeloma and Leukemia, 18, S289. https://doi.org/10.1016/j.clml.2018.07.229
|
[38]
|
Ratuszny, D., Skripuletz, T., Wegner, F., et al. (2020) Case Report: Daratumumab in a Patient with Severe Refractory Anti-NMDA Receptor Encephalitis. Frontiers in Neurology, 11, Arti-cle 602102.
https://doi.org/10.3389/fneur.2020.602102
|
[39]
|
Lazzarin, S.M., Vabanesi, M., Cecchetti, G., et al. (2020) Refrac-tory Anti-NMDAR Encephalitis Successfully Treated with Bortezomib and Associated Movements Disorders Controlled with Tramadol: A Case Report with Literature Review. Journal of Neurology, 267, 2462-2468. https://doi.org/10.1007/s00415-020-09988-w
|
[40]
|
Scheibe, F., Ostendorf, L., Prüss, H., et al. (2022) Daratu-mumab for Treatment-Refractory Antibody-Mediated Diseases in Neurology. European Journal of Neurology, 29, 1847-1854. https://doi.org/10.1111/ene.15266
|
[41]
|
Berg, S.L. and Chamberlain, M.C. (2003) Systemic Chemo-therapy, Intrathecal Chemotherapy, and Symptom Management in the Treatment of Leptomeningeal Metastasis. Current Oncology Reports, 5, 29-40.
https://doi.org/10.1007/s11912-003-0084-9
|
[42]
|
Tatencloux, S., Chretien, P., Rogemond, V., et al. (2015) In-trathecal Treatment of Anti-N-Methyl-d-Aspartate Receptor Encephalitis in Children. Developmental Medicine and Child Neurology, 57, 95-99.
https://doi.org/10.1111/dmcn.12545
|
[43]
|
Wang, D., Wu, Y., Ji, Z., et al. (2020) A Refractory Anti-NMDA Re-ceptor Encephalitis Successfully Treated by Bilateral Salpingo-Oophorectomy and Intrathecal Injection of Methotrexate and Dexamethasone: A Case Report. Journal of International Medical Research, 48, No. 10. https://doi.org/10.1177/0300060520925666
|
[44]
|
Eaton, J.E., Kleinholz-Owens, P., Sriram, S. and Pawate, S. (2021) Intrathecal Methotrexate—Another Tool for the Treatment of Refractory Autoimmune Encephalitis-Single Institution Cohort and Literature Review. Journal of the Neurological Sciences, 431, Article ID: 120042. https://doi.org/10.1016/j.jns.2021.120042
|
[45]
|
Liba, Z., Sebronova, V., Komarek, V., Sediva, A. and Sedlacek, P. (2013) Prevalence and Treatment of Anti-NMDA Receptor Encephalitis. The Lancet Neurology, 12, 424-425. https://doi.org/10.1016/S1474-4422(13)70070-X
|
[46]
|
Yang, X., Zhu, H., Ren, H., et al. (2018) Utility and Safety of Intrathecal Methotrexate Treatment in Severe Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Pilot Study. Chi-nese Medical Journal, 131, 156-160.
https://doi.org/10.4103/0366-6999.222327
|
[47]
|
Bhojwani, D., Sabin, N.D., Howard, S.C., et al. (2014) Metho-trexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia. Journal of Clini-cal Oncology, 32, 949-959.
https://doi.org/10.1200/JCO.2013.53.0808
|
[48]
|
Polman, C.H., O’Connor, P.W., Havrdova, E., et al. (2006) A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. The New England Journal of Medicine, 354, 899-910.
https://doi.org/10.1056/NEJMoa044397
|
[49]
|
Hottinger, A.F., de Micheli, R., Guido, V., Karampera, A., et al. (2018) Natalizumab May Control Immune Checkpoint Inhibitor-Induced Limbic Encephalitis. Neurology Neuroim-munology & Neuroinflammation, 5, e439.
https://doi.org/10.1212/NXI.0000000000000439
|
[50]
|
Basin, S., Perrin, J., Michot, J.M., Lambotte, O. and Cauquil, C. (2021) Severe Anti-PD1-Related Meningoencephalomyelitis Successfully Treated with Anti-Integrin α4 Therapy. Eu-ropean Journal of Cancer, 145, 230-233.
https://doi.org/10.1016/j.ejca.2020.12.014
|
[51]
|
Bastiaansen, A., de Jongste, A., de Bruijn, M., et al. (2021) Phase II Trial of Natalizumab for the Treatment of Anti-Hu Associated Paraneoplastic Neurological Syndromes. Neu-ro-Oncology Advances, 3, vdab145.
https://doi.org/10.1093/noajnl/vdab145
|
[52]
|
Blackburn, K.M., Denney, D.A., Hopkins, S.C. and Vernino S.A., (2022) Low Recruitment in a Double-Blind, Placebo-Controlled Trial of Ocrelizumab for Autoimmune Encephalitis: A Case Series and Review of Lessons Learned. Neurology and Therapy, 11, 893-903. https://doi.org/10.1007/s40120-022-00327-x
|
[53]
|
Dubey, D., Britton, J., McKeon, A., et al. (2020) Randomized Placebo-Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy. Annals of Neurology, 87, 313-323. https://doi.org/10.1002/ana.25655
|
[54]
|
Wong, K.H., Cudkowicz, M., Singleton, J., et al. (2022) The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor En-cephalitis. Neuorology, 99, s39.
|
[55]
|
Wickel, J., Chung, H., Platzer, S., et al. (2020) Generate-Boost: Study Protocol for a Prospective, Multicenter, Randomized Controlled, Double-Blinded Phase II Trial to Evaluate Efficacy and Safety of Bortezomib in Patients with Severe Autoimmune Encephalitis. Current Controlled Trials in Cardiovascular Medicine, 21, Article No. 625.
https://doi.org/10.1186/s13063-020-04516-7
|